← Leaderboards
Wilfried Rossoll
Mayo Clinic Jacksonville
$12,130,299
Attributed
$16,483,562
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,483,562 · 11
By mechanism
RF1$7,892,922 · 2
R01$5,971,587 · 4
R21$1,272,677 · 3
R33$892,876 · 1
R61$453,500 · 1
Top collaborators
- Junmin Peng3 shared
- James Shorter3 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Lea Tenenholz Grinberg$17,312,791
- Seiko Ikezu$2,629,396
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsAnimal ModelProteinsMolecularMouse ModelPathway InteractionsCellsIn VivoNerve DegenerationPathologyCell TypeIn VitroProteomicsNeurodegenerative DisordersEffective TherapyFunctional DisorderBaseProteomeComplexDefectAffectAxonMotor Neurons
Grant awards (24)
Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias$722,870
R01 · FY2025 · AG · contact PI
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$705,885
R01 · FY2025 · AG · contact PI
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesis$1,171,075
R01 · FY2024 · AG
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$693,758
R01 · FY2024 · AG · contact PI
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$730,483
R01 · FY2023 · AG · contact PI
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesis$455,000
RF1 · FY2023 · AG
NUP50 as a modifier and risk factor for TDP-43 pathology in FTD/ALS$430,267
R21 · FY2023 · AG · contact PI
Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias$304,220
RF1 · FY2023 · AG · contact PI
Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias$2,183,377
RF1 · FY2022 · AG · contact PI
High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)$434,563
R33 · FY2021 · NS · contact PI
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesis$4,950,325
RF1 · FY2020 · AG
High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)$458,313
R33 · FY2020 · NS · contact PI
High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)$453,500
R61 · FY2019 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$342,344
R01 · FY2019 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$171,172
R01 · FY2019 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$342,344
R01 · FY2018 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$342,344
R01 · FY2017 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$396,483
R01 · FY2016 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$13,803
R01 · FY2016 · NS · contact PI
RNA Processing Defects in SMA and Their Contribution to the Disease Phenotype$339,026
R01 · FY2015 · NS · contact PI
Spinal Muscular Atrophy: Cell-based drug screens for treatment of axonal defects$193,750
R21 · FY2011 · NS · contact PI
Spinal Muscular Atrophy: Cell-based drug screens for treatment of axonal defects$232,500
R21 · FY2010 · NS · contact PI
Spinal muscular atrophy: a novel role of SMN in axonal ribonucleoprotein complexe$224,910
R21 · FY2008 · HD · contact PI
Spinal muscular atrophy: a novel role of SMN in axonal ribonucleoprotein complexe$191,250
R21 · FY2007 · HD · contact PI